Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOV1501 (ABL001) in Advanced Solid Tumors
NCT03292783Phase 1Completed
- Sponsor
- ABL Bio
- Start
- Sep 2017
- Primary completion
- Mar 2021
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tovecimig in solid tumor (advanced stage), sponsored by ABL Bio. Primary endpoint: Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs). Started Sep 2017; status: completed.
02
Drugs
tovecimig
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03292783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292783.